A Review on Molecular Mechanisms Linking Gut Dysbiosis to Chronic Metabolic, Cardiovascular, and Renal Disorders

Review Article

Abstract

The human gastrointestinal tract serves as a dense reservoir of microbiome whose metabolic outputs act as critical molecular bridges between the external environment and host internal physiology. Commensal mutualism preserves epithelial barrier function, coordinates immune tolerance, and regulates host energy harvesting. Similarly, compositional and functional gut dysbiosis disrupts barrier integrity, instigating pathobiont outgrowth, localized tissue destruction, and pathologic translocation of bioactive molecular intermediates. Structural disruptions in apical junctional complexes permit mucosal penetration of pathogen-associated molecular patterns, notably lipopolysaccharides, into systemic circulation. This microbially derived metabolic endotoxemia triggers chronic, low-grade systemic inflammation through toll-like receptor 4 signaling cascades across distal organ systems. Pathological shifts in microbial catabolism alter systemic concentrations of key regulatory metabolites. The selective depletion of beneficial short-chain fatty acids impairs host metabolic homeostasis, attenuates free fatty acid receptor 2 and 3 activation, and downregulates histone deacetylase inhibition. Parallel aberrant metabolic activity accelerates production of toxic intermediates, including trimethylamine, which undergoes hepatic conversion to pro-atherogenic trimethylamine N-oxide, alongside the excessive accumulation of protein-derived uremic toxins such as indoxyl sulfate and p-cresyl sulfate. These biochemical intermediates accelerate the pathophysiology of type 2 diabetes mellitus, systemic hypertension, atherosclerosis, and chronic kidney disease through oxidative stress, vascular endothelial dysfunction, and profibrotic signaling. Restoring microbially mediated metabolic equilibrium via dietary modulations, targeted postbiotic or probiotic supplementation, microbial enzymatic inhibition, and fecal microbiota transplantation could be a pivotal frontier in precision medicine.